BrightGene Bio-Medical Technology Valuation

Q: What is the Fair Price of 688166 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688166 (CN¥30.35) is trading below our estimate of [[fair value]] (CN¥57.75)

Is 688166 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688166 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688166 (CN¥30.35) is trading below our estimate of fair value (CN¥57.75)

Significantly Below Fair Value: 688166 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688166?

Key metric: As 688166 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688166. This is calculated by dividing 688166's market cap by their current earnings.
What is 688166's PE Ratio?
PE Ratio	68.1x
Earnings	CN¥188.08m
Market Cap	CN¥12.81b

688166 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.6x
Enterprise Value/EBITDA	54.6x
PEG Ratio	2x

Price to Earnings Ratio vs Peers

How does 688166's PE Ratio compare to its peers?

The above table shows the PE ratio for 688166 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.8x
603456 Zhejiang Jiuzhou Pharmaceutical	19.2x	20.2%	CN¥13.4b
002737 Sunflower Pharmaceutical GroupLtd	13.7x	n/a	CN¥11.7b
002287 Tibet Cheezheng Tibetan Medicine	19.8x	n/a	CN¥11.7b
600129 Chongqing Taiji Industry(Group)Ltd	22.5x	31.0%	CN¥13.7b
688166 BrightGene Bio-Medical Technology	68.1x	34.8%	CN¥12.8b

Price-To-Earnings vs Peers: 688166 is expensive based on its Price-To-Earnings Ratio (68.1x) compared to the peer average (18.8x).

Price to Earnings Ratio vs Industry

How does 688166's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688166 is expensive based on its Price-To-Earnings Ratio (68.1x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 688166's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688166 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	68.1x
Fair PE Ratio	34.7x

Price-To-Earnings vs Fair Ratio: 688166 is expensive based on its Price-To-Earnings Ratio (68.1x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%